CEL-SCI Corp
CVM
Market cap $29.2M

0.3937 USD

-0.0089

2.21%

At close Jan 21, 4:00 PM EST

After hours

0.3983

+0.0046

1.17%

1 day

-2.21%

5 days

-1.33%

1 month

-43.60%

3 months

-56.26%

6 months

-72.08%

Year to date

-5.11%

1 year

-84.13%

5 years

-96.81%

10 years

-97.50%

About: CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Employees: 44

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,823 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 11

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

1% less funds holding

Funds holding: 67 [Q2] → 66 (-1) [Q3]

1.82% less ownership

Funds ownership: 11.53% [Q2] → 9.72% (-1.82%) [Q3]

13% less capital invested

Capital invested by funds: $7.25M [Q2] → $6.32M (-$923K) [Q3]

16% less call options, than puts

Call options by funds: $138K | Put options by funds: $165K

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CVM.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about CVM published over the past 30 days

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2024 results: set to commence confirmatory study that could bring new standard of care to head & neck cancer.

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Announces Closing of $5 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $5 million offering.

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Pricing of $5 Million Public Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $5 million public offering.

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces proposed public offering of common stock.

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study.

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Stock Picks From Seeking Alpha's October 2024 New Analysts

In October, 42 new analysts joined Seeking Alpha, sharing diverse investment ideas and strategies, from biotech to real estate. Highlighted strong buy recommendations include MicroStrategy, CorMedix, Hewlett Packard Enterprise, Vertex Pharmaceuticals, and several others. Readers are encouraged to engage with the new analysts, share thoughts on their picks, and join the conversation.

Stock Picks From Seeking Alpha's October 2024 New Analysts

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025.

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--FDA's ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients.

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer.

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO2024--CEL-SCI's Multikine Increased 5-Year Survival Rate in Locally Advanced Resectable Head & Neck Cancer Patients Deemed to be in the Treatment Group.

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

See News Rankings

Charts implemented using Lightweight Charts™